Equities research analysts forecast that American Renal Associates Holdings Inc (NYSE:ARA) will report earnings of $0.15 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for American Renal Associates’ earnings, with the lowest EPS estimate coming in at $0.13 and the highest estimate coming in at $0.16. American Renal Associates reported earnings per share of $0.19 during the same quarter last year, which would indicate a negative year-over-year growth rate of 21.1%. The firm is expected to issue its next quarterly earnings results on Tuesday, November 13th.
On average, analysts expect that American Renal Associates will report full year earnings of $0.60 per share for the current financial year, with EPS estimates ranging from $0.56 to $0.65. For the next financial year, analysts forecast that the firm will report earnings of $0.62 per share, with EPS estimates ranging from $0.56 to $0.70. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow American Renal Associates.
American Renal Associates (NYSE:ARA) last issued its earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. American Renal Associates had a negative net margin of 1.11% and a positive return on equity of 19.60%. The company had revenue of $217.18 million for the quarter, compared to analyst estimates of $203.70 million.
American Renal Associates traded up $0.19, hitting $21.03, on Friday, according to MarketBeat.com. 168,028 shares of the company were exchanged, compared to its average volume of 157,811. The company has a current ratio of 1.07, a quick ratio of 1.10 and a debt-to-equity ratio of 5.30. American Renal Associates has a fifty-two week low of $9.91 and a fifty-two week high of $24.07. The firm has a market capitalization of $676.61 million, a P/E ratio of 30.65, a PEG ratio of 1.34 and a beta of 1.96.
Several hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of American Renal Associates by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 52,733 shares of the company’s stock valued at $831,000 after purchasing an additional 5,478 shares during the last quarter. Franklin Resources Inc. grew its position in shares of American Renal Associates by 0.9% in the first quarter. Franklin Resources Inc. now owns 756,287 shares of the company’s stock valued at $14,256,000 after purchasing an additional 6,478 shares during the last quarter. Barclays PLC lifted its stake in shares of American Renal Associates by 23.9% during the first quarter. Barclays PLC now owns 52,295 shares of the company’s stock valued at $986,000 after buying an additional 10,093 shares during the period. Rhumbline Advisers purchased a new position in shares of American Renal Associates during the second quarter valued at approximately $195,000. Finally, Element Capital Management LLC purchased a new position in shares of American Renal Associates during the first quarter valued at approximately $263,000. Institutional investors and hedge funds own 89.39% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Further Reading: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.